Dr. Kim is a medical neuro-oncologist specializing primary brain tumors and systemic tumors with central nervous system metastasis. He graduated from Yonsei University, College of Medicine in Seoul, Korea. He completed residency in internal medicine at the UMDNJ-Robert Wood Johnson Medical School in New Brunswick, New Jersey, hematology-oncology fellowship at the Brown University in Providence, Rhode Island and neuro-oncology fellowship at Massachusetts General Hospital/Harvard Medical School in Boston, Massachusetts.

He worked at the Neuro-Oncology Branch at the National Cancer Institute/National Institutes of Health (NCI/NIH) as a Senior Staff Physician for several years and was highly instrumental to build a successful neuro-oncology program at the NCI/NIH. He also served as the Director of the Neuro-Oncology fellowship training program.

While at NIH, he participated in a pivotal Bevacizumab clinical trial which led to the approval of the drug by FDA for the treatment of recurrent glioblastoma that is now widely accepted as the standard care for many types of recurrent brain tumors. As a part of joint effort to train fellows together, he also worked at the Johns Hopkins University Hospital. After leaving NCI/NIH, he worked at the University of Massachusetts as the Director of Neuro-Oncology before joining Thomas Jefferson University Hospital in Philadelphia, PA in 2010 as the Director of Clinical Research. In addition to the management of primary brain tumors and systemic malignancies with CNS metastasis, he is also interested in the treatment of skull base tumors and rare CNS malignancies base on each patient’s molecular genetic profiling.

He is conducting many clinical trials involving new chemotherapeutic agents, immunotherapies, antiangiogenic agents and oncolytic virus therapies. He is particularly interested in the treatment of elderly population with innovative minimally invasive surgical techniques, focal radiation therapies, novel therapeutic devices and approaches like nano-technology and molecular targeted therapies in an attempt to minimize potential side effects of extensive surgery, radiation and chemotherapy and improve quality of life. He has published papers in many respected journals and wrote book chapters. He is well known nationally and internationally and he collaborates with many peer institutions across the country.